Future directions in glioblastoma therapy

Area of Science:

• Neuro-oncology
• Cancer therapy
• Molecular biology

Background:

• Standard glioblastoma (GBM) treatment evolved with surgery, radiation, and temozolomide for newly diagnosed cases.
• Bevacizumab is now common for recurrent GBM, improving radiographic response and progression-free survival.
• Interpreting imaging after treatment and managing antiangiogenic effects pose significant clinical challenges.

Purpose of the Study:

• To review current glioblastoma treatment standards and challenges.
• To discuss the role and controversies of bevacizumab in GBM management.
• To highlight the impact of molecular profiling on understanding GBM heterogeneity and developing targeted therapies.

Main Methods:

• Literature review of glioblastoma treatment standards.
• Analysis of bevacizumab efficacy and limitations in GBM.
• Summary of findings from molecular profiling projects like The Cancer Genome Atlas (TCGA).

Main Results:

• Standard care for newly diagnosed GBM includes surgery, radiation, and temozolomide.
• Bevacizumab shows efficacy in radiographic response and progression-free survival for recurrent GBM, but overall survival benefit is debated.
• Molecular subtyping of GBM reveals distinct tumor biology and outcomes, paving the way for targeted treatments.

Conclusions:

• Despite treatment advances, glioblastoma management remains complex, particularly regarding imaging interpretation and recurrent disease.
• Bevacizumab's role in overall survival is controversial, and effective therapies for progression after antiangiogenic treatment are lacking.
• Molecular insights into GBM heterogeneity are crucial for developing future rational and targeted therapeutic strategies for specific subtypes.